The Drug That Might Rewrite Pancreatic Cancer's Brutal Math

Why This Drug Can Do What Others Couldn't

For decades, KRAS was considered "undruggable." Think of it like a light switch stuck in the "on" position, constantly telling cancer cells to grow. The protein's surface is smooth and featureless; there's almost nowhere for a drug to grab hold. First-generation drugs like Amgen's Lumakras (sotorasib) and BMS's Krazati (adagrasib) finally cracked the code, but only for one specific KRAS mutation called G12C.

Pancreatic cancer mostly doesn't care about G12C inhibitors because its dominant mutation is KRAS G12D, a different beast entirely.

Daraxonrasib takes a fundamentally different approach. Instead of targeting a single mutation in its inactive state, the drug goes after active RAS proteins across multiple mutations (G12D, G12V, G12A, and more). It works by recruiting a naturally occurring protein called cyclophilin A to essentially glue itself to RAS and lock it into an inactive shape. Picture it like jamming a doorstop under that stuck light switch; the signal finally shuts off.

This mutation-agnostic design is why daraxonrasib can work in pancreatic cancer, where over 90% of cases carry RAS mutations. It's fishing with a net instead of a single hook.

Building on a Blockbuster Foundation

These first-line results don't exist in a vacuum. They come on the heels of Phase 3 data from the RASolute 302 trial in previously treated pancreatic cancer patients. That trial hit its primary endpoint with a median overall survival of 13.2 months for daraxonrasib versus just 6.7 months for standard chemo. A hazard ratio of 0.40 (meaning a 60% reduction in the risk of death) was staggeringly significant, with a p-value below 0.0001.

In second-line pancreatic cancer, where outcomes are typically measured in weeks rather than months, those numbers felt almost disorienting. Revolution's stock surged roughly 41% on the news.

Now, with the first-line data looking strong, Revolution has launched RASolute 303: a Phase 3 trial that will randomize untreated patients to receive chemotherapy alone, daraxonrasib alone, or the combination. Enrollment is already underway.

The Elephant in the Boardroom

When a biotech company has a drug that could reshape the standard of care in one of oncology's deadliest cancers, big pharma comes knocking. And knock they did.

The Wall Street Journal reported in early January 2026 that AbbVie was in advanced discussions for a $20 billion-plus acquisition of Revolution. AbbVie denied it. Then reports emerged that Merck was in talks, targeting a valuation between $28 billion and $32 billion. Those negotiations reportedly fell apart over price.

Revolution has stayed quiet, sticking to its policy of not commenting on speculation. CEO Mark Goldsmith fielded thinly veiled questions about "strategic transactions" at the JP Morgan Healthcare Conference in January and gave nothing away. But with its stock up 65% from January 2025, the acquisition math is only getting more compelling.

Big pharma is staring down patent cliffs and pipeline gaps. Revolution is sitting on potentially the most important KRAS drug in oncology. The courtship isn't over; it's just on intermission.

What Comes Next

The RASolute 303 trial will be the definitive test. If daraxonrasib can replicate its second-line survival advantage in the first-line setting (where patients are healthier and treatment options matter even more), it won't just be a blockbuster. It'll be the new foundation of pancreatic cancer treatment.

For a disease that has humbled nearly every drug that came before it, daraxonrasib is writing a chapter that oncologists haven't seen in a generation. The data is early, the patient numbers are modest, and Phase 3 confirmation is still pending. But for the first time in a long time, pancreatic cancer's brutal math is starting to look a little less certain.

Novartis Just Spent $925M on a Drug That Can't Beat the Reigning Champ

Novartis killed two late-stage trials for its next-gen blood thinner after it couldn't outperform Eliquis, the $14.4 billion anticoagulant behemoth. The $925 million bet on abelacimab just got a lot narrower, and the implications ripple across the entire Factor XIa race.